The Latest Breaking News from BDX

Becton Dickinson & Co. (BDX) is expected to report steady growth for its fiscal fourth quarter ended September 2023, scheduled to be released on November 9. While the stock is witnessing weakness over the past month, will the quarterly report be able to spur a rally? Read on.

Concerns over high inflation, the Fed’s hawkish stance to control it, and an economic slowdown have led to immense stock market volatility. Therefore, it could be wise to invest in stocks with decades of dividend-paying history, such as Johnson & Johnson (JNJ), AbbVie (ABBV), and Becton, Dickinson and Company (BDX),…

Someone with a lot of money to spend has taken a bearish stance on Becton, Dickinson (NYSE:BDX). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Despite a decline in inflation in July, persistent concerns over a potential recession could keep the market volatile in the upcoming months. Therefore, it could be wise to invest in dividend stocks AbbVie (ABBV), Emerson Electric (EMR), and Becton Dickinson (BDX) to navigate the market volatility with solid passive income.…

Becton, Dickinson (NYSE:BDX) has outperformed the market over the past 10 years by 1.98% on an annualized basis producing an average annual return of 12.93%. Currently, Becton, Dickinson has a market capitalization of $70.95 billion.

Becton, Dickinson (NYSE:BDX) has outperformed the market over the past 20 years by 3.34% on an annualized basis producing an average annual return of 10.37%. Currently, Becton, Dickinson has a market capitalization of $71.95 billion.

Becton Dickinson and Co (NYSE:BDX) will acquire Parata Systems from Frazier Healthcare Partners for $1.525 billion.  Parata offers a portfolio of pharmacy automation solutions to reduce costs, enhance patient safety and improve the patient experience.  Significant macro trends such as clinician shortages, wage inflation, centralization of pharmacy services, and increased clinical demands…

Becton, Dickinson (NYSE:BDX) has outperformed the market over the past 10 years by 1.48% on an annualized basis producing an average annual return of 13.59%. Currently, Becton, Dickinson has a market capitalization of $72.68 billion.

Growing demand for critical surgical procedures and increasing investments in R&D should drive the medical devices industry’s growth. Prominent medical device companies Becton Dickinson (BDX) and Intuitive Surgical (ISRG) are well-positioned to capitalize on the industry tailwinds. But which of these stocks is a better buy now? Read more to…

The stock market has witnessed a massive sell-off lately on concerns over the Fed’s aggressive interest rate hikes to fight the decade-high inflation. Many analysts expect the economy to slip into recession due to the Fed’s monetary policy tightening. Since the medical device industry is known to be one of…

Becton Dickinson and Co (NYSE:BDX) reported Q2 FY22 revenues of $5.01 billion, up 2.1% Y/Y (3.9% on a currency-neutral basis), better than the consensus of $4.85 billion. Revenue was driven by base revenue growth of 8.2% as reported, 10.2% currency-neutral, partially offset by the decline in COVID-only testing revenues to $214 million…